JP2021534762A5 - - Google Patents

Info

Publication number
JP2021534762A5
JP2021534762A5 JP2021510019A JP2021510019A JP2021534762A5 JP 2021534762 A5 JP2021534762 A5 JP 2021534762A5 JP 2021510019 A JP2021510019 A JP 2021510019A JP 2021510019 A JP2021510019 A JP 2021510019A JP 2021534762 A5 JP2021534762 A5 JP 2021534762A5
Authority
JP
Japan
Prior art keywords
sequence numbers
sequence
numbers
isolated polynucleotide
antigen
Prior art date
Application number
JP2021510019A
Other languages
English (en)
Japanese (ja)
Other versions
JP7490915B2 (ja
JPWO2020043152A5 (https=
JP2021534762A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/103215 external-priority patent/WO2020043152A1/en
Publication of JP2021534762A publication Critical patent/JP2021534762A/ja
Publication of JP2021534762A5 publication Critical patent/JP2021534762A5/ja
Publication of JPWO2020043152A5 publication Critical patent/JPWO2020043152A5/ja
Application granted granted Critical
Publication of JP7490915B2 publication Critical patent/JP7490915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510019A 2018-08-29 2019-08-29 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用 Active JP7490915B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018103050 2018-08-29
CNPCT/CN2018/103050 2018-08-29
CNPCT/CN2019/083918 2019-04-23
CN2019083918 2019-04-23
PCT/CN2019/103215 WO2020043152A1 (en) 2018-08-29 2019-08-29 Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof

Publications (4)

Publication Number Publication Date
JP2021534762A JP2021534762A (ja) 2021-12-16
JP2021534762A5 true JP2021534762A5 (https=) 2022-09-01
JPWO2020043152A5 JPWO2020043152A5 (https=) 2022-09-01
JP7490915B2 JP7490915B2 (ja) 2024-05-28

Family

ID=69643948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510019A Active JP7490915B2 (ja) 2018-08-29 2019-08-29 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用

Country Status (11)

Country Link
US (1) US11932698B2 (https=)
EP (1) EP3844282A4 (https=)
JP (1) JP7490915B2 (https=)
KR (1) KR102879284B1 (https=)
CN (1) CN112639102B (https=)
AU (1) AU2019327913A1 (https=)
CA (1) CA3111087A1 (https=)
IL (1) IL281098A (https=)
SG (1) SG11202101773WA (https=)
TW (1) TW202024330A (https=)
WO (1) WO2020043152A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
WO2018140573A1 (en) * 2017-01-26 2018-08-02 Sangamo Therapeutics, Inc. B-cell engineering
EP3715368A1 (en) * 2019-03-28 2020-09-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells
KR20220078568A (ko) * 2019-08-14 2022-06-10 모드맵 테라퓨틱스 인코포레이티드 Lrp5 단백질에 결합하는 항체 및 사용 방법
CN110964750A (zh) * 2019-11-13 2020-04-07 沣潮医药科技（上海）有限公司 携带基因元件组合的嵌合抗原受体细胞文库、制备和筛选方法及用途
US12264190B2 (en) * 2020-04-24 2025-04-01 Astrazeneca Ab Compositions and methods of treating cancer with chimeric antigen receptors
US20240252641A1 (en) * 2020-05-05 2024-08-01 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
GB202006820D0 (en) * 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202008688D0 (en) * 2020-06-09 2020-07-22 Cancer Research Tech Ltd Chimeric antigen receptor cell
JP2023532347A (ja) * 2020-06-29 2023-07-27 セル メディカ，インコーポレイテッド キメラ抗原受容体の緊張性シグナル伝達を減少させる方法および組成物
JP7138989B1 (ja) 2020-08-04 2022-09-20 セレンジーン インコーポレイテッド メソテリンに特異的に結合する抗メソテリンキメラ抗原受容体
GB202012181D0 (en) * 2020-08-05 2020-09-16 Autolus Ltd Chimeric receptor
WO2022037562A1 (en) * 2020-08-17 2022-02-24 Nanjing Legend Biotech Co., Ltd. Engineered immunoresponsive cells and uses thereof
EP4263612A4 (en) * 2020-12-18 2025-04-02 Bioardis LLC Mesothelin binding molecules and uses thereof
AU2022222688B2 (en) * 2021-02-16 2025-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to mesothelin polypeptides
WO2022232277A1 (en) * 2021-04-27 2022-11-03 TCR2 Therapeutics Inc. COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS AND TGFβR SWITCH
JP7487989B2 (ja) * 2021-05-26 2024-05-21 セレンジーン インコーポレイテッド 抗メソテリンｓｃＦｖを含むキメリック抗原受容体及びその用途
WO2022257984A1 (zh) * 2021-06-08 2022-12-15 南京驯鹿医疗技术有限公司 一种增强型嵌合抗原受体(car)细胞的制备及其应用
WO2023020472A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Mesothelin-targetting antibodies and uses thereof in cancer therapies
CN115724942A (zh) * 2021-09-02 2023-03-03 广东菲鹏制药股份有限公司 TGFβRII活性改造突变体及其应用
CN115746123A (zh) * 2021-09-02 2023-03-07 广东菲鹏制药股份有限公司 TGFβRII突变体及其应用
CN114015720A (zh) * 2021-09-29 2022-02-08 昆明市延安医院 具有靶向高强度杀瘤活性的Mesothelin嵌合抗原受体修饰的T细胞的制备方法
KR20240109293A (ko) * 2021-10-06 2024-07-10 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 암 치료에서 fshr을 표적으로 하는 이중특이 t세포 활성제와 사용 방법
TW202323281A (zh) * 2021-10-14 2023-06-16 美商泰尼歐生物公司 間皮素結合蛋白及其用途
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
US20250242023A1 (en) * 2021-10-22 2025-07-31 Regents Of The University Of Minnesota Genetically engineered t cell receptors
EP4461747A4 (en) * 2022-01-06 2026-04-15 Oricell Therapeutics Co Ltd ANTIGEN-BINDING PROTEIN TARGETTING MSLN AND ITS USE
CN114560949B (zh) * 2022-03-07 2023-09-26 中国人民解放军空军军医大学 一种具有增强car-t细胞抗肿瘤能力的嵌合抗原受体、d-car-t细胞及其应用
CN116284409A (zh) * 2022-07-08 2023-06-23 上海优替济生生物医药有限公司 Gpc3 car-t细胞及其在制备治疗癌症的药物中的用途
WO2024088371A1 (zh) * 2022-10-28 2024-05-02 原启生物科技(上海)有限责任公司 靶向msln的抗原结合蛋白
WO2024096592A1 (ko) * 2022-11-02 2024-05-10 주식회사 셀렌진 메소텔린에 대한 친화도가 상승된 키메릭 항원 수용체 및 이의 용도
CN116019939A (zh) * 2022-11-24 2023-04-28 华中科技大学同济医学院附属协和医院 靶向msln的分子探针以及用途
KR20250163331A (ko) * 2023-03-23 2025-11-20 내셔날 리서치 카운실 오브 캐나다 항-메소텔린 (msln) 단일 도메인 항체 및 치료 작제물
CN118109416B (zh) * 2023-03-30 2024-11-22 广州百吉生物制药有限公司 功能增强型工程化免疫细胞及其制备和应用
WO2024259305A1 (en) * 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
WO2024259070A2 (en) * 2023-06-14 2024-12-19 Merck Sharp & Dohme Llc Chimeric antigen receptors and use thereof
CN119708251A (zh) * 2023-09-27 2025-03-28 北京大学 一种利用cd27逆转t和car-t细胞pd1信号的工程化细胞方法
CN118147105B (zh) * 2024-05-09 2024-08-02 西宝生物科技（上海）股份有限公司 一种蔗糖磷酸化酶的高效制备方法
CN119859615A (zh) * 2024-12-31 2025-04-22 广州安捷生物医学技术有限公司 一种靶向成纤维细胞激活蛋白的car-msc细胞及其制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7405053B2 (en) * 2003-05-20 2008-07-29 The University Court Of The University Of Glasgow Materials and methods relating to G-protein coupled receptor oligomers
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
KR102437522B1 (ko) 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
US20140004121A1 (en) * 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
CN104769103B (zh) 2012-09-04 2018-06-08 塞勒克提斯公司 多链嵌合抗原受体和其用途
CN104955845B (zh) * 2012-09-27 2018-11-16 美国政府(由卫生和人类服务部的部长所代表) 间皮素抗体和引起有效的抗肿瘤活性的方法
CN102875685B (zh) 2012-09-29 2013-12-25 郑骏年 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
PL3546572T3 (pl) 2013-05-13 2024-07-22 Cellectis Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
MX2015015638A (es) 2013-05-13 2016-10-28 Cellectis Metodos para diseñar celulas t altamente activas para inmunoterapia.
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
ES2928000T3 (es) 2014-06-06 2022-11-14 Memorial Sloan Kettering Cancer Center Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
AU2016243124A1 (en) * 2015-03-27 2017-11-02 University Of Southern California CAR T-cell therapy directed to LHR for the treatment of solid tumors
CN104877032B (zh) * 2015-06-26 2018-12-11 中国医学科学院血液病医院（血液学研究所） Cd33特异性嵌合抗原受体及其应用
AU2016317936A1 (en) 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
WO2018132695A1 (en) 2017-01-13 2018-07-19 Celdara Medical, Llc Chimeric antigen receptors targeting tim-1

Similar Documents

Publication Publication Date Title
JP2021534762A5 (https=)
JPWO2020043152A5 (https=)
TWI769537B (zh) 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途
CN108026169B (zh) 抗人cd137的完全人抗体及其应用
JP2021508469A5 (https=)
CN112574307A (zh) 抗人Claudin18.2抗体及其应用
JP2021514664A5 (https=)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
JP2021510521A5 (https=)
JP2020510422A5 (https=)
JP2018518540A5 (https=)
JP2018502050A5 (https=)
BRPI0707824A2 (pt) proteÍna de ligaÇço a antÍgeno, e, mÉtodos de neutralizaÇço da ativaÇço de um receptor de tirosina quinase, de inibiÇço de angiogÊnese, de reduÇço de crescimento de tumor e de produÇço de uma proteÍna de ligaÇço a antÍgeno
JP2013527761A5 (https=)
JPWO2019129221A5 (https=)
HRP20190605T1 (hr) Protutijela anti-fxi i postupci njihove uporabe
JP2013527762A5 (https=)
JP2021530244A5 (https=)
JP2020502233A5 (https=)
EP3904381A1 (en) Antibody fusion protein, preparation method therefor and application thereof
JP2020515277A5 (https=)
JP2021512652A5 (https=)
JP2020522488A5 (https=)
CN111712521A (zh) Cd38蛋白抗体及其应用
TW202300516A (zh) Ｐｄ—１結合蛋白及其醫藥用途